{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:06:45Z","timestamp":1788887205415,"version":"build-2803163510"},"reference-count":79,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K99 CA296996"],"award-info":[{"award-number":["K99 CA296996"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R21 NS141756"],"award-info":[{"award-number":["R21 NS141756"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 CA262311"],"award-info":[{"award-number":["R01 CA262311"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P01 CA118816"],"award-info":[{"award-number":["P01 CA118816"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P50 CA097257"],"award-info":[{"award-number":["P50 CA097257"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UH3 CA298961"],"award-info":[{"award-number":["UH3 CA298961"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U54 CA302452"],"award-info":[{"award-number":["U54 CA302452"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Trenchard Family Charitable Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Molecular profiling is increasingly important for risk stratification and individualization of treatment recommendations for patients with meningioma. Prior investigations have established the genomic architecture of meningioma, but the distribution of meningioma copy number alterations (CNAs) and short somatic variants (SSVs) across demographic groups is incompletely understood. Here we define a prospective, consecutive benchmark for meningioma CNAs and SSVs across demographic groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective next-generation DNA sequencing was performed on 1,104 tumor samples from 1,044 consecutive patients who were treated for meningioma or whose meningiomas underwent molecular testing at a large academic medical center in a major US city from 2019 to 2025. Univariate and multivariate regression analyses were performed to evaluate associations between demographic characteristics, CNAs, and SSVs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Meningiomas from Asian males were enriched in high-risk molecular features, including (1) copy number deletion of chromosomes 1p, 6q, and 14q, (2) copy number gain of chromosome 1q, (3) chromosome 1p\/22q codeletion or co-occurrent 1p loss\/1q gain, and (4) CDKN2A\/B homozygous deletion. In contrast, meningiomas from females were enriched in low-risk molecular features, including SSVs in TRAF7, AKT1, and PIK3CA. The molecular architecture of meningiomas from Hispanic and non-Hispanic White individuals appeared similar, though Hispanic ethnicity was a unique independent predictor of low-grade disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this US-based cohort, the distribution of meningioma CNAs and SSVs varies across demographic groups. Asian males appear to have an increased risk of clinically aggressive meningioma due to enrichment in high-risk molecular features that were previously unappreciated in this patient population. Molecularly favorable meningiomas are more common in females, and low-grade meningiomas are more common in Hispanic individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag196","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:36:58Z","timestamp":1787053018000},"source":"Crossref","is-referenced-by-count":0,"title":["Prospective consecutive genomic profiling defines the distribution of meningioma molecular alterations across demographic groups"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6300-0776","authenticated-orcid":false,"given":"Brooke C","family":"Braman","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of California San Francisco , San Francisco, California,","place":["USA"]},{"name":"Department of Pathology, University of California San Francisco , San Francisco, California,","place":["USA"]},{"name":"Department of Neurological Surgery, University of California San Francisco , San Francisco, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9665-7629","authenticated-orcid":false,"given":"Minh P","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California San Francisco , San Francisco, California,","place":["USA"]},{"name":"Department of Pathology, University of California San Francisco , San Francisco, California,","place":["USA"]},{"name":"Department of Neurological Surgery, University of California San Francisco , San Francisco, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7371-7059","authenticated-orcid":false,"given":"Kanish","family":"Mirchia","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California San Francisco , San Francisco, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8464-6041","authenticated-orcid":false,"given":"Ramin A","family":"Morshed","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California San Francisco , San Francisco, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8302-5008","authenticated-orcid":false,"given":"Nancy Ann","family":"Oberheim Bush","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California San Francisco , San Francisco, California,","place":["USA"]},{"name":"Department of Neurology, University of California San Francisco , San Francisco, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zora","family":"Arum","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California San Francisco , San Francisco, California,","place":["USA"]},{"name":"Department of Pathology, University of California San Francisco , San Francisco, California,","place":["USA"]},{"name":"Department of Neurological Surgery, University of California San Francisco , San Francisco, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-0757","authenticated-orcid":false,"given":"Javier E","family":"Villanueva-Meyer","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of California San Francisco , San Francisco, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8924-5853","authenticated-orcid":false,"given":"William C","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California San Francisco , San Francisco, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7674-8937","authenticated-orcid":false,"given":"Jessica","family":"Van Ziffle","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California San Francisco , San Francisco, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Rajkovic","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California San Francisco , San Francisco, California,","place":["USA"]},{"name":"Department of Obstetrics\/Gynecology and Reproductive Sciences, University of California San Francisco , San Francisco, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California San Francisco , San Francisco, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4634-8830","authenticated-orcid":false,"given":"Walter Patrick","family":"Devine","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California San Francisco , San Francisco, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8300-7261","authenticated-orcid":false,"given":"Arie","family":"Perry","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California San Francisco , San Francisco, California,","place":["USA"]},{"name":"Department of Neurological Surgery, University of California San Francisco , San Francisco, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9299-8864","authenticated-orcid":false,"given":"David R","family":"Raleigh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California San Francisco , San Francisco, California,","place":["USA"]},{"name":"Department of Pathology, University of California San Francisco , San Francisco, California,","place":["USA"]},{"name":"Department of Neurological Surgery, University of California San Francisco , San Francisco, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026090812112070500_noag196-B1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2018\u20132022","volume":"27","author":"Price","year":"2025","journal-title":"Neuro-Oncol."},{"key":"2026090812112070500_noag196-B2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.5414\/NP301160","article-title":"Clinicopathologic features of incidental meningiomas: a review of the literature and the University of Rochester autopsy experience","volume":"38","author":"Johnson","year":"2019","journal-title":"Clin Neuropathol"},{"key":"2026090812112070500_noag196-B3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0090-3019(87)90005-X","article-title":"Incidental meningiomas in autopsy study","volume":"27","author":"Nakasu","year":"1987","journal-title":"Surg Neurol"},{"key":"2026090812112070500_noag196-B4","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1056\/NEJMoa070972","article-title":"Incidental findings on brain MRI in the general population","volume":"357","author":"Vernooij","year":"2007","journal-title":"N Engl J Med"},{"key":"2026090812112070500_noag196-B5","doi-asserted-by":"publisher","first-page":"i5","DOI":"10.1093\/noajnl\/vdad020","article-title":"The joint impacts of sex and race\/ethnicity on incidence of grade 1 versus grades 2\u20133 meningioma across the lifespan","volume":"5","author":"Walsh","year":"2023","journal-title":"Neurooncol Adv"},{"key":"2026090812112070500_noag196-B6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/jnci\/djae253","article-title":"Grade-stratified meningioma risk among individuals who are non-Hispanic black and interactions with male sex","volume":"117","author":"Walsh","year":"2025","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2026090812112070500_noag196-B7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/neuonc\/noae239","article-title":"Meningiomas: sex-specific differences and prognostic implications of a chromosome X loss","volume":"27","author":"Berghaus","year":"2025","journal-title":"Neuro-Oncol"},{"key":"2026090812112070500_noag196-B8","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noag115","article-title":"Epidemiological and clinical data link depot medroxyprogesterone acetate to meningioma","author":"Braman","year":"2026","journal-title":"Neuro-Oncol"},{"key":"2026090812112070500_noag196-B9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1227\/NEU.0000000000001751","article-title":"Racial and socioeconomic disparities in patients with meningioma: a retrospective cohort study","volume":"90","author":"Jackson","year":"2022","journal-title":"Neurosurgery"},{"key":"2026090812112070500_noag196-B10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/neuonc\/noad223","article-title":"Association of county-level socioeconomic status with meningioma incidence and outcomes","volume":"26","author":"Pugazenthi","year":"2024","journal-title":"Neuro-Oncol"},{"key":"2026090812112070500_noag196-B11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s11060-023-04393-5","article-title":"Associations of race and socioeconomic status with outcomes after intracranial meningioma resection: a systematic review and meta-analysis","volume":"163","author":"Lei","year":"2023","journal-title":"J Neurooncol"},{"key":"2026090812112070500_noag196-B12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3171\/2011.3.JNS101748","article-title":"Treatment and survival of patients with nonmalignant intracranial meningioma: results from the surveillance, epidemiology, and end results program of the national cancer institute: clinical article","volume":"115","author":"Cahill","year":"2011","journal-title":"J Neurosurg"},{"key":"2026090812112070500_noag196-B13","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3171\/2024.1.JNS231633","article-title":"Variations in the genomic profiles and clinical behavior of meningioma by racial and ethnic group","volume":"141","author":"Tabor","year":"2024","journal-title":"J Neurosurg"},{"key":"2026090812112070500_noag196-B14","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science (1979)"},{"key":"2026090812112070500_noag196-B15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3171\/2019.8.JNS191266","article-title":"Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas","volume":"133","author":"Youngblood","year":"2020","journal-title":"J Neurosurg"},{"key":"2026090812112070500_noag196-B16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat Genet"},{"key":"2026090812112070500_noag196-B17","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0002-9440(10)61737-3","article-title":"Alterations of the tumor suppressor genes CDKN2A (p16), p14, CDKN2B (p15), and CDKN2C (p18) in atypical and anaplastic meningiomas","volume":"159","author":"Bostr\u00f6m","year":"2001","journal-title":"Am J Pathol"},{"key":"2026090812112070500_noag196-B18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","article-title":"CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas","volume":"140","author":"Sievers","year":"2020","journal-title":"Acta Neuropathol"},{"key":"2026090812112070500_noag196-B19","doi-asserted-by":"publisher","first-page":"djv377","DOI":"10.1093\/jnci\/djv377","article-title":"TERT promoter mutations and risk of recurrence in meningioma","volume":"108","author":"Sahm","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2026090812112070500_noag196-B20","doi-asserted-by":"publisher","first-page":"109228","DOI":"10.18632\/oncotarget.22650","article-title":"Intratumoral heterogeneity and TERT promoter mutations in progressive\/higher-grade meningiomas","volume":"8","author":"Juratli","year":"2017","journal-title":"Oncotarget"},{"key":"2026090812112070500_noag196-B21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0165-4608(98)00209-X","article-title":"Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas","volume":"110","author":"Lamszus","year":"1999","journal-title":"Cancer Genet Cytogenet"},{"key":"2026090812112070500_noag196-B22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/a:1006086723607","article-title":"Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma","volume":"41","author":"Ozaki","year":"1999","journal-title":"J Neurooncol"},{"key":"2026090812112070500_noag196-B23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S0165-4608(99)00249-6","article-title":"High-resolution analysis of chromosome arm 1p alterations in meningioma","volume":"120","author":"Bello","year":"2000","journal-title":"Cancer Genet Cytogenet"},{"key":"2026090812112070500_noag196-B24","doi-asserted-by":"publisher","first-page":"14433","DOI":"10.1038\/ncomms14433","article-title":"Integrated genomic analyses of de novo pathways underlying atypical meningiomas","volume":"8","author":"Harmanc\u0131","year":"2017","journal-title":"Nat Commun"},{"key":"2026090812112070500_noag196-B25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","article-title":"Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities","volume":"54","author":"Choudhury","year":"2022","journal-title":"Nat Genet"},{"key":"2026090812112070500_noag196-B26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","article-title":"A clinically applicable integrative molecular classification of meningiomas","volume":"597","author":"Nassiri","year":"2021","journal-title":"Nature"},{"key":"2026090812112070500_noag196-B27","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1038\/s41591-024-03167-4","article-title":"Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"2026090812112070500_noag196-B28","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1200\/JCO.21.00784","article-title":"Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated","volume":"39","author":"Maas","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026090812112070500_noag196-B29","doi-asserted-by":"publisher","first-page":"eabm6247","DOI":"10.1126\/sciadv.abm6247","article-title":"Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies","volume":"8","author":"Bayley","year":"2022","journal-title":"Sci Adv"},{"key":"2026090812112070500_noag196-B30","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/neuonc\/noab213","article-title":"A molecularly integrated grade for meningioma","volume":"24","author":"Driver","year":"2022","journal-title":"Neuro-Oncol"},{"key":"2026090812112070500_noag196-B31","doi-asserted-by":"publisher","first-page":"i18","DOI":"10.1093\/neuonc\/noy136","article-title":"Advances in multidisciplinary therapy for meningiomas","volume":"21","author":"Brastianos","year":"2019","journal-title":"Neuro-Oncol."},{"key":"2026090812112070500_noag196-B32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2017.168","article-title":"Advances in meningioma genetics: novel therapeutic opportunities","volume":"14","author":"Preusser","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"2026090812112070500_noag196-B33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/neuonc\/noae170","article-title":"cIMPACT-NOW update 8: clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas","volume":"27","author":"Sahm","year":"2025","journal-title":"Neuro-Oncol"},{"key":"2026090812112070500_noag196-B34","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41591-025-04141-4","article-title":"Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 alliance A071401 trial","volume":"32","author":"Brastianos","year":"2026","journal-title":"Nat Med"},{"key":"2026090812112070500_noag196-B35","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1227\/neu.0000000000003624","article-title":"The rationale for early adjuvant radiotherapy after gross total resection of atypical meningioma","volume":"97","author":"Raleigh","year":"2025","journal-title":"Neurosurgery"},{"key":"2026090812112070500_noag196-B36","article-title":"NCCN clinical practice guidelines in oncology: central nervous system cancers version 2.2025","author":"Nabors","year":"2025","journal-title":"Natl Compr Cancer Netw"},{"key":"2026090812112070500_noag196-B37","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro-Oncol"},{"key":"2026090812112070500_noag196-B38","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncol"},{"key":"2026090812112070500_noag196-B39","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1093\/neuonc\/noae082","article-title":"Meningioma: international consortium on meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients","volume":"26","author":"Wang","year":"2024","journal-title":"Neuro-Oncol"},{"key":"2026090812112070500_noag196-B40","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1038\/s41591-023-02586-z","article-title":"Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses","volume":"29","author":"Chen","year":"2023","journal-title":"Nat Med"},{"key":"2026090812112070500_noag196-B41","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1038\/s41591-023-02642-8","article-title":"Meningioma risk stratification with a targeted gene-expression biomarker","volume":"29","year":"2023","journal-title":"Nat Med"},{"key":"2026090812112070500_noag196-B42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/neuonc\/noad212","article-title":"A 34-gene expression biomarker predicts meningioma outcomes and radiotherapy responses","volume":"26","author":"Raleigh","year":"2024","journal-title":"Neuro-Oncol"},{"key":"2026090812112070500_noag196-B43","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/neuonc\/noae198","article-title":"A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence","volume":"27","author":"Nguyen","year":"2025","journal-title":"Neuro-Oncol"},{"key":"2026090812112070500_noag196-B44","doi-asserted-by":"publisher","first-page":"e191870","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026090812112070500_noag196-B45","doi-asserted-by":"publisher","first-page":"e212640","DOI":"10.1001\/jamanetworkopen.2021.2640","article-title":"Participation of black US residents in clinical trials of 24 cardiovascular drugs granted FDA approval, 2006-2020","volume":"4","author":"Chen","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026090812112070500_noag196-B46","doi-asserted-by":"publisher","first-page":"e2113749","DOI":"10.1001\/jamanetworkopen.2021.13749","article-title":"Analysis of female enrollment and participant sex by burden of disease in US clinical trials between 2000 and 2020","volume":"4","author":"Steinberg","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026090812112070500_noag196-B47","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/neuonc\/noac011","article-title":"A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH revitalization act","volume":"24","author":"Reihl","year":"2022","journal-title":"Neuro-Oncol"},{"key":"2026090812112070500_noag196-B48","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1038\/s41467-025-61063-y","article-title":"Pan-cancer copy number analysis identifies optimized size thresholds and co-occurrence models for individualized risk stratification","volume":"16","author":"Nguyen","year":"2025","journal-title":"Nat Commun"},{"key":"2026090812112070500_noag196-B49","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.1038\/s41467-025-60734-0","article-title":"Distribution of copy number alterations and impact of chromosome arm call thresholds for meningioma","volume":"16","author":"Patel","year":"2025","journal-title":"Nat Commun"},{"key":"2026090812112070500_noag196-B50","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1001\/jamaoncol.2025.0329","article-title":"Chromosome 1p loss and 1q gain for grading of meningioma","volume":"11","author":"Landry","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026090812112070500_noag196-B51","doi-asserted-by":"publisher","first-page":"vdae092","DOI":"10.1093\/noajnl\/vdae092","article-title":"Response to immune checkpoint inhibition in a meningioma with DNA mismatch repair deficiency","volume":"6","author":"Nguyen","year":"2024","journal-title":"Neurooncol Adv"},{"key":"2026090812112070500_noag196-B52","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/neuonc\/noab118","article-title":"Activity of PD-1 blockade with nivolumab among patients with recurrent atypical\/anaplastic meningioma: phase II trial results","volume":"24","author":"Bi","year":"2022","journal-title":"Neuro-Oncol"},{"key":"2026090812112070500_noag196-B53","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1001\/jamaoncol.2026.0507","article-title":"Prospective genomic profiling consecutive meningiomas","volume":"12","author":"Nguyen","year":"2026","journal-title":"JAMA Oncol"},{"key":"2026090812112070500_noag196-B54","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s41588-024-01747-1","article-title":"Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution","volume":"56","author":"Lucas","year":"2024","journal-title":"Nat Genet"},{"key":"2026090812112070500_noag196-B55","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.cell.2017.09.048","article-title":"Comprehensive analysis of hypermutation in human cancer","volume":"171","author":"Campbell","year":"2017","journal-title":"Cell"},{"key":"2026090812112070500_noag196-B56","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(06)70625-1","article-title":"Histological classification and molecular genetics of meningiomas","volume":"5","author":"Riemenschneider","year":"2006","journal-title":"Lancet Neurol"},{"key":"2026090812112070500_noag196-B57","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1200\/JCO.2003.07.156","article-title":"New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology","volume":"21","author":"Ma\u00edllo","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026090812112070500_noag196-B58","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/neuonc\/nov316","article-title":"Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma","volume":"18","author":"Abedalthagafi","year":"2016","journal-title":"Neuro-Oncol"},{"key":"2026090812112070500_noag196-B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00190","article-title":"Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade","volume":"2018","author":"Dunn","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2026090812112070500_noag196-B60","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41525-017-0014-7","article-title":"Genomic landscape of high-grade meningiomas","volume":"2","author":"Bi","year":"2017","journal-title":"Npj Genomic Med"},{"key":"2026090812112070500_noag196-B61","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/annonc\/mdx763","article-title":"Progestin-associated shift of meningioma mutational landscape","volume":"29","author":"Peyre","year":"2018","journal-title":"Ann Oncol"},{"key":"2026090812112070500_noag196-B62","doi-asserted-by":"publisher","first-page":"n37","DOI":"10.1136\/bmj.n37","article-title":"Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study","volume":"372","author":"Weill","year":"2021","journal-title":"BMJ."},{"key":"2026090812112070500_noag196-B63","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/jnnp-2021-326138","article-title":"Cyproterone acetate and risk of meningioma: a nationwide cohort study","volume":"93","author":"Mikkelsen","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026090812112070500_noag196-B64","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1111\/ene.15423","article-title":"Risk of intracranial meningioma with three potent progestogens: a population-based case\u2013control study","volume":"29","author":"Hoisnard","year":"2022","journal-title":"Eur J Neurol"},{"key":"2026090812112070500_noag196-B65","doi-asserted-by":"publisher","first-page":"100928","DOI":"10.1016\/j.lanepe.2024.100928","article-title":"Prolonged use of nomegestrol acetate and risk of intracranial meningioma: a population-based cohort study","volume":"42","author":"Nguyen","year":"2024","journal-title":"Lancet Reg Health - Eur"},{"key":"2026090812112070500_noag196-B66","doi-asserted-by":"publisher","first-page":"e078078","DOI":"10.1136\/bmj-2023-078078","article-title":"Use of progestogens and the risk of intracranial meningioma: national case-control study","volume":"384","author":"Roland","year":"2024","journal-title":"BMJ."},{"key":"2026090812112070500_noag196-B67","doi-asserted-by":"publisher","first-page":"e083981","DOI":"10.1136\/bmj-2024-083981","article-title":"Oral contraceptives with progestogens desogestrel or levonorgestrel and risk of intracranial meningioma: national case-control study","volume":"389","author":"Roland","year":"2025","journal-title":"BMJ"},{"key":"2026090812112070500_noag196-B68","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/neuonc\/noaf228","article-title":"Hormonal contraceptives and the risk of meningioma: a Swedish register-based case-control study","volume":"28","author":"Tettamanti","year":"2026","journal-title":"Neuro-Oncol"},{"key":"2026090812112070500_noag196-B69","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/neuonc\/noaf267","article-title":"Mounting evidence implicates medroxyprogesterone acetate in meningioma risk, but mechanisms require further investigation","volume":"28","author":"Braman","year":"2026","journal-title":"Neuro-Oncol"},{"key":"2026090812112070500_noag196-B70","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaneurol.2025.3011","article-title":"Depot medroxyprogesterone acetate and risk of meningioma in the US","volume":"82","author":"Xiao","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026090812112070500_noag196-B71","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.3390\/cancers16193362","article-title":"The association between medroxyprogesterone acetate exposure and meningioma","volume":"16","author":"Griffin","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026090812112070500_noag196-B72","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s11060-025-05402-5","article-title":"Risk of intracranial meningioma requiring surgical intervention among recent hormonal contraceptives users","volume":"176","author":"Chen","year":"2026","journal-title":"J Neurooncol"},{"key":"2026090812112070500_noag196-B73","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S0140-6736(23)01088-7","article-title":"Cause-specific mortality by county, race, and ethnicity in the USA, 2000\u201319: a systematic analysis of health disparities","volume":"402","author":"Dwyer-Lindgren","year":"2023","journal-title":"The Lancet"},{"key":"2026090812112070500_noag196-B74","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/nop\/npz059","article-title":"Relative survival after diagnosis with a primary brain or other Central nervous system tumor in the national program of cancer registries, 2004 to 2014","volume":"7","author":"Ostrom","year":"2020","journal-title":"Neurooncol Pract"},{"key":"2026090812112070500_noag196-B75","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/jnci\/djad069","article-title":"Cancer mortality rates by racial and ethnic groups in the United States, 2018-2020","volume":"115","author":"Haque","year":"2023","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2026090812112070500_noag196-B76","doi-asserted-by":"publisher","first-page":"11812","DOI":"10.1038\/s41598-022-15916-x","article-title":"Trends in national and county-level hispanic mortality in the United States, 2011\u20132020","volume":"12","author":"Sarraju","year":"2022","journal-title":"Sci Rep"},{"key":"2026090812112070500_noag196-B77","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1111\/j.1467-6494.2009.00598.x","article-title":"Resiliency in the face of disadvantage: do Hispanic cultural characteristics protect health outcomes?","volume":"77","author":"Gallo","year":"2009","journal-title":"J Pers"},{"key":"2026090812112070500_noag196-B78","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3390\/ijerph10051786","article-title":"The Hispanic paradox and older adults\u2019 disabilities: is there a healthy migrant effect?","volume":"10","author":"Thomson","year":"2013","journal-title":"Int J Environ Res Public Health"},{"key":"2026090812112070500_noag196-B79","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S1470-2045(25)00422-X","article-title":"The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis","volume":"26","author":"Groff","year":"2025","journal-title":"Lancet Oncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag196\/70715085\/noag196.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag196\/70715085\/noag196.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:12:11Z","timestamp":1788883931000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article\/doi\/10.1093\/neuonc\/noag196\/8766570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":79,"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag196","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"noag196"}}